{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T22:46:27Z","timestamp":1791585987921,"version":"4.3.4"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2022,5,12]],"date-time":"2022-05-12T00:00:00Z","timestamp":1652313600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,5,12]],"date-time":"2022-05-12T00:00:00Z","timestamp":1652313600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"name":"Guangzhou Science and Technology Project","award":["201803010027"],"award-info":[{"award-number":["201803010027"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82174022"],"award-info":[{"award-number":["82174022"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100021171","name":"Guangdong Basic and Applied Basic Research Foundation","doi-asserted-by":"crossref","award":["2019B1515120051"],"award-info":[{"award-number":["2019B1515120051"]}],"id":[{"id":"10.13039\/501100021171","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cancer Res Clin Oncol"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1007\/s00432-022-04036-8","type":"journal-article","created":{"date-parts":[[2022,5,12]],"date-time":"2022-05-12T19:24:56Z","timestamp":1652383496000},"page":"2743-2757","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Attenuated Toxoplasma gondii enhances the antitumor efficacy of anti-PD1 antibody by altering the tumor microenvironment in a pancreatic cancer mouse model"],"prefix":"10.1007","volume":"148","author":[{"given":"Said Ahmed","family":"Bahwal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane J.","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lilin","family":"E","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taofang","family":"Hao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiancong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vern B.","family":"Carruthers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaming","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8145-1476","authenticated-orcid":false,"given":"Xingwang","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,5,12]]},"reference":[{"key":"4036_CR1","doi-asserted-by":"publisher","first-page":"178","DOI":"10.4103\/0974-777X.145248","volume":"6","author":"SR Agrawal","year":"2014","unstructured":"Agrawal SR, Singh V, Ingale S et al (2014) Toxoplasmosis of spinal cord in acquired immunodeficiency syndrome patient presenting as paraparesis: a rare entity. J Glob Infect Dis 6:178\u2013181. https:\/\/doi.org\/10.4103\/0974-777X.145248","journal-title":"J Glob Infect Dis"},{"key":"4036_CR2","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.3892\/ijo.2016.3586","volume":"49","author":"Y Akiyama","year":"2016","unstructured":"Akiyama Y, Nonomura C, Kondou R et al (2016) Immunological effects of the anti-programmed death-1 antibody on human peripheral blood mononuclear cells. Int J Oncol 49:1099\u20131107. https:\/\/doi.org\/10.3892\/ijo.2016.3586","journal-title":"Int J Oncol"},{"key":"4036_CR3","first-page":"409","volume":"3","author":"MB Atkins","year":"1997","unstructured":"Atkins MB, Robertson MJ, Gordon M et al (1997) Phase I evaluation of intravenous recombinant human interleukin 12 in patients with advanced malignancies. Clin Cancer Res 3:409\u2013417","journal-title":"Clin Cancer Res"},{"key":"4036_CR4","doi-asserted-by":"publisher","first-page":"3842","DOI":"10.1158\/0008-5472.CAN-12-1974","volume":"73","author":"JR Baird","year":"2013","unstructured":"Baird JR, Fox BA, Sanders KL et al (2013a) Avirulent Toxoplasma gondii generates therapeutic antitumor immunity by reversing immunosuppression in the ovarian cancer microenvironment. Cancer Res 73:3842\u20133851. https:\/\/doi.org\/10.1158\/0008-5472.CAN-12-1974","journal-title":"Cancer Res"},{"key":"4036_CR5","doi-asserted-by":"publisher","first-page":"469","DOI":"10.4049\/jimmunol.1201209","volume":"190","author":"JR Baird","year":"2013","unstructured":"Baird JR, Byrne KT, Lizotte PH et al (2013b) Immune-mediated regression of established B16F10 melanoma by intratumoral injection of attenuated Toxoplasma gondii protects against rechallenge. J Immunol 190:469\u2013478. https:\/\/doi.org\/10.4049\/jimmunol.1201209","journal-title":"J Immunol"},{"key":"4036_CR6","doi-asserted-by":"publisher","first-page":"6","DOI":"10.21037\/tgh.2020.04.03","volume":"6","author":"J Bian","year":"2021","unstructured":"Bian J, Almhanna K (2021) Pancreatic cancer and immune checkpoint inhibitors-still a long way to go. Transl Gastroenterol Hepatol 6:6. https:\/\/doi.org\/10.21037\/tgh.2020.04.03","journal-title":"Transl Gastroenterol Hepatol"},{"key":"4036_CR7","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1038\/s41591-018-0014-x","volume":"24","author":"M Binnewies","year":"2018","unstructured":"Binnewies M, Roberts EW, Kersten K et al (2018) Understanding the tumor immune microenvironment (TIME) for effective therapy. Nat Med 24:541\u2013550. https:\/\/doi.org\/10.1038\/s41591-018-0014-x","journal-title":"Nat Med"},{"key":"4036_CR8","doi-asserted-by":"publisher","first-page":"2455","DOI":"10.1056\/NEJMoa1200694","volume":"366","author":"JR Brahmer","year":"2012","unstructured":"Brahmer JR, Tykodi SS, Chow LQ et al (2012) Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 366:2455\u20132465. https:\/\/doi.org\/10.1056\/NEJMoa1200694","journal-title":"N Engl J Med"},{"key":"4036_CR9","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1006190","volume":"13","author":"R Cattaneo","year":"2017","unstructured":"Cattaneo R, Russell SJ (2017) How to develop viruses into anticancer weapons. PLoS Pathog 13:e1006190. https:\/\/doi.org\/10.1371\/journal.ppat.1006190","journal-title":"PLoS Pathog"},{"key":"4036_CR10","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1038\/s41392-020-00377-3","volume":"6","author":"J Chen","year":"2021","unstructured":"Chen J, Sun HW, Yang YY et al (2021) Reprogramming immunosuppressive myeloid cells by activated T cells promotes the response to anti-PD-1 therapy in colorectal cancer. Signal Transduct Targ Ther 6:4. https:\/\/doi.org\/10.1038\/s41392-020-00377-3","journal-title":"Signal Transduct Targ Ther"},{"key":"4036_CR11","doi-asserted-by":"publisher","first-page":"9518","DOI":"10.1158\/0008-5472.CAN-07-0175","volume":"67","author":"CE Clark","year":"2007","unstructured":"Clark CE, Hingorani SR, Mick R et al (2007) Dynamics of the immune reaction to pancreatic cancer from inception to invasion. Cancer Res 67:9518\u20139527. https:\/\/doi.org\/10.1158\/0008-5472.CAN-07-0175","journal-title":"Cancer Res"},{"key":"4036_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.canlet.2008.09.037","volume":"279","author":"CE Clark","year":"2009","unstructured":"Clark CE, Beatty GL, Vonderheide RH (2009) Immunosurveillance of pancreatic adenocarcinoma: insights from genetically engineered mouse models of cancer. Cancer Lett 279:1\u20137. https:\/\/doi.org\/10.1016\/j.canlet.2008.09.037","journal-title":"Cancer Lett"},{"key":"4036_CR13","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1004047","volume":"10","author":"CD Dupont","year":"2014","unstructured":"Dupont CD, Christian DA, Selleck EM et al (2014) Parasite fate and involvement of infected cells in the induction of CD4+ and CD8+ T cell responses to Toxoplasma gondii. PLoS Pathog 10:e1004047. https:\/\/doi.org\/10.1371\/journal.ppat.1004047","journal-title":"PLoS Pathog"},{"key":"4036_CR14","doi-asserted-by":"publisher","first-page":"5200","DOI":"10.1128\/IAI.00954-07","volume":"75","author":"F Dzierszinski","year":"2007","unstructured":"Dzierszinski F, Pepper M, Stumhofer JS et al (2007) Presentation of Toxoplasma gondii antigens via the endogenous major histocompatibility complex class I pathway in nonprofessional and professional antigen-presenting cells. Infect Immun 75:5200\u20135209. https:\/\/doi.org\/10.1128\/IAI.00954-07","journal-title":"Infect Immun"},{"key":"4036_CR53","first-page":"1502","volume":"21","author":"LL E","year":"2021","unstructured":"E LL, Yang ZF, Bahwal SA et al (2021) Construction and phenotypic identification of a non-replicating Toxoplasma\u00a0uracil auxotroph. J Trop Med (China) 21:1502\u20131508","journal-title":"J Trop Med (China)"},{"key":"4036_CR15","doi-asserted-by":"publisher","first-page":"4266","DOI":"10.1158\/1078-0432.CCR-11-3114","volume":"18","author":"C Feig","year":"2012","unstructured":"Feig C, Gopinathan A, Neesse A et al (2012) The pancreas cancer microenvironment. Clin Cancer Res 18:4266\u20134276. https:\/\/doi.org\/10.1158\/1078-0432.CCR-11-3114","journal-title":"Clin Cancer Res"},{"key":"4036_CR16","doi-asserted-by":"publisher","first-page":"3744","DOI":"10.1128\/IAI.00287-10","volume":"78","author":"BA Fox","year":"2010","unstructured":"Fox BA, Bzik DJ (2010) Avirulent uracil auxotrophs based on disruption of orotidine-5\u2019-monophosphate decarboxylase elicit protective immunity to Toxoplasma gondii. Infect Immun 78:3744\u20133752. https:\/\/doi.org\/10.1128\/IAI.00287-10","journal-title":"Infect Immun"},{"key":"4036_CR17","doi-asserted-by":"publisher","first-page":"2148","DOI":"10.1128\/IAI.02756-14","volume":"83","author":"BA Fox","year":"2015","unstructured":"Fox BA, Bzik DJ (2015) Nonreplicating, cyst-defective type II Toxoplasma gondii vaccine strains stimulate protective immunity against acute and chronic infection. Infect Immun 83:2148\u20132155. https:\/\/doi.org\/10.1128\/IAI.02756-14","journal-title":"Infect Immun"},{"key":"4036_CR18","doi-asserted-by":"publisher","DOI":"10.4161\/onci.26296","volume":"2","author":"BA Fox","year":"2013","unstructured":"Fox BA, Sanders KL, Bzik DJ (2013a) Non-replicating Toxoplasma gondii reverses tumor-associated immunosuppression. Oncoimmunology 2:e26296. https:\/\/doi.org\/10.4161\/onci.26296","journal-title":"Oncoimmunology"},{"key":"4036_CR19","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1016\/j.pt.2013.07.001","volume":"29","author":"BA Fox","year":"2013","unstructured":"Fox BA, Sanders KL, Chen S et al (2013b) Targeting tumors with nonreplicating Toxoplasma gondii uracil auxotroph vaccines. Trends Parasitol 29:431\u2013437. https:\/\/doi.org\/10.1016\/j.pt.2013.07.001","journal-title":"Trends Parasitol"},{"key":"4036_CR20","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pgen.1006189","volume":"12","author":"BA Fox","year":"2016","unstructured":"Fox BA, Sanders KL, Rommereim LM et al (2016) Secretion of rhoptry and dense granule effector proteins by nonreplicating Toxoplasma gondii uracil auxotrophs controls the development of antitumor immunity. PLoS Genet 12:e1006189. https:\/\/doi.org\/10.1371\/journal.pgen.1006189","journal-title":"PLoS Genet"},{"key":"4036_CR21","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1006523","volume":"13","author":"BA Fox","year":"2017","unstructured":"Fox BA, Butler KL, Guevara RB et al (2017) Cancer therapy in a microbial bottle: uncorking the novel biology of the protozoan Toxoplasma gondii. PLoS Pathog 13:e1006523. https:\/\/doi.org\/10.1371\/journal.ppat.1006523","journal-title":"PLoS Pathog"},{"issue":"1148\u20131161","key":"4036_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2018.09.024","volume":"49","author":"CS Garris","year":"2018","unstructured":"Garris CS, Arlauckas SP, Kohler RH et al (2018) Successful anti-PD-1 cancer immunotherapy requires T cell-dendritic cell crosstalk involving the cytokines IFN-gamma and IL-12. Immunity 49(1148\u20131161):e7. https:\/\/doi.org\/10.1016\/j.immuni.2018.09.024","journal-title":"Immunity"},{"key":"4036_CR23","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1038\/s41571-020-0363-5","volume":"17","author":"WJ Ho","year":"2020","unstructured":"Ho WJ, Jaffee EM, Zheng L (2020) The tumour microenvironment in pancreatic cancer\u2014clinical challenges and opportunities. Nat Rev Clin Oncol 17:527\u2013540. https:\/\/doi.org\/10.1038\/s41571-020-0363-5","journal-title":"Nat Rev Clin Oncol"},{"key":"4036_CR24","doi-asserted-by":"publisher","first-page":"1326","DOI":"10.1158\/1078-0432.CCR-17-3099","volume":"24","author":"ZI Hu","year":"2018","unstructured":"Hu ZI, Shia J, Stadler ZK et al (2018) Evaluating mismatch repair deficiency in pancreatic adenocarcinoma: challenges and recommendations. Clin Cancer Res 24:1326\u20131336. https:\/\/doi.org\/10.1158\/1078-0432.CCR-17-3099","journal-title":"Clin Cancer Res"},{"key":"4036_CR25","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1128\/EC.00358-08","volume":"8","author":"MH Huynh","year":"2009","unstructured":"Huynh MH, Carruthers VB (2009) Tagging of endogenous genes in a Toxoplasma gondii strain lacking Ku80. Eukaryot Cell 8:530\u2013539. https:\/\/doi.org\/10.1128\/EC.00358-08","journal-title":"Eukaryot Cell"},{"key":"4036_CR26","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1136\/gutjnl-2017-314225","volume":"67","author":"V Iorio","year":"2018","unstructured":"Iorio V, Rosati A, D\u2019Auria R et al (2018) Combined effect of anti-BAG3 and anti-PD-1 treatment on macrophage infiltrate, CD8(+) T cell number and tumour growth in pancreatic cancer. Gut 67:780\u2013782. https:\/\/doi.org\/10.1136\/gutjnl-2017-314225","journal-title":"Gut"},{"key":"4036_CR27","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1016\/j.immuni.2015.08.006","volume":"43","author":"NS Joshi","year":"2015","unstructured":"Joshi NS, Akama-Garren EH, Lu Y et al (2015) Regulatory T cells in tumor-associated tertiary lymphoid structures suppress anti-tumor T Cell responses. Immunity 43:579\u2013590. https:\/\/doi.org\/10.1016\/j.immuni.2015.08.006","journal-title":"Immunity"},{"key":"4036_CR28","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1056\/NEJMp1709968","volume":"377","author":"S Lemery","year":"2017","unstructured":"Lemery S, Keegan P, Pazdur R (2017) First FDA approval agnostic of cancer site\u2014when a biomarker defines the indication. N Engl J Med 377:1409\u20131412. https:\/\/doi.org\/10.1056\/NEJMp1709968","journal-title":"N Engl J Med"},{"key":"4036_CR29","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1016\/j.ejca.2017.06.016","volume":"83","author":"P Lohneis","year":"2017","unstructured":"Lohneis P, Sinn M, Bischoff S et al (2017) Cytotoxic tumour-infiltrating T lymphocytes influence outcome in resected pancreatic ductal adenocarcinoma. Eur J Cancer 83:290\u2013301. https:\/\/doi.org\/10.1016\/j.ejca.2017.06.016","journal-title":"Eur J Cancer"},{"key":"4036_CR30","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1136\/gutjnl-2020-320726","volume":"70","author":"C Luchini","year":"2021","unstructured":"Luchini C, Brosens LAA, Wood LD et al (2021) Comprehensive characterisation of pancreatic ductal adenocarcinoma with microsatellite instability: histology, molecular pathology and clinical implications. Gut 70:148\u2013156. https:\/\/doi.org\/10.1136\/gutjnl-2020-320726","journal-title":"Gut"},{"key":"4036_CR31","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1158\/2326-6066.CIR-14-0027","volume":"2","author":"ER Lutz","year":"2014","unstructured":"Lutz ER, Wu AA, Bigelow E et al (2014) Immunotherapy converts nonimmunogenic pancreatic tumors into immunogenic foci of immune regulation. Cancer Immunol Res 2:616\u2013631. https:\/\/doi.org\/10.1158\/2326-6066.CIR-14-0027","journal-title":"Cancer Immunol Res"},{"key":"4036_CR32","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1158\/2326-6066.CIR-18-0061","volume":"7","author":"HS Ma","year":"2019","unstructured":"Ma HS, Poudel B, Torres ER et al (2019) A CD40 agonist and PD-1 antagonist antibody reprogram the microenvironment of nonimmunogenic tumors to allow T-cell-mediated anticancer activity. Cancer Immunol Res 7:428\u2013442. https:\/\/doi.org\/10.1158\/2326-6066.CIR-18-0061","journal-title":"Cancer Immunol Res"},{"key":"4036_CR33","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1038\/s41575-018-0005-x","volume":"15","author":"JP Neoptolemos","year":"2018","unstructured":"Neoptolemos JP, Kleeff J, Michl P et al (2018) Therapeutic developments in pancreatic cancer: current and future perspectives. Nat Rev Gastroenterol Hepatol 15:333\u2013348. https:\/\/doi.org\/10.1038\/s41575-018-0005-x","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"4036_CR34","doi-asserted-by":"publisher","first-page":"5187","DOI":"10.1158\/1078-0432.CCR-17-0741","volume":"23","author":"A Orillion","year":"2017","unstructured":"Orillion A, Hashimoto A, Damayanti N et al (2017) Entinostat neutralizes myeloid-derived suppressor cells and enhances the antitumor effect of PD-1 inhibition in murine models of lung and renal cell carcinoma. Clin Cancer Res 23:5187\u20135201. https:\/\/doi.org\/10.1158\/1078-0432.CCR-17-0741","journal-title":"Clin Cancer Res"},{"key":"4036_CR35","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.00508-21","volume":"89","author":"SN Payne","year":"2021","unstructured":"Payne SN, Emmerich PB, Davis NM et al (2021) Novel murine pancreatic tumor model demonstrates immunotherapeutic control of tumor progression by a Toxoplasma gondii protein. Infect Immun 89:e0050821. https:\/\/doi.org\/10.1128\/IAI.00508-21","journal-title":"Infect Immun"},{"key":"4036_CR36","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1258\/ijsa.2012.012189","volume":"24","author":"H Pott Jr","year":"2013","unstructured":"Pott H Jr, Castelo A (2013) Isolated cerebellar toxoplasmosis as a complication of HIV infection. Int J STD AIDS 24:70\u201372. https:\/\/doi.org\/10.1258\/ijsa.2012.012189","journal-title":"Int J STD AIDS"},{"key":"4036_CR37","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1016\/j.ccr.2012.04.024","volume":"21","author":"Y Pylayeva-Gupta","year":"2012","unstructured":"Pylayeva-Gupta Y, Lee KE, Hajdu CH et al (2012) Oncogenic Kras-induced GM-CSF production promotes the development of pancreatic neoplasia. Cancer Cell 21:836\u2013847. https:\/\/doi.org\/10.1016\/j.ccr.2012.04.024","journal-title":"Cancer Cell"},{"key":"4036_CR38","doi-asserted-by":"publisher","first-page":"9577","DOI":"10.1073\/pnas.0502272102","volume":"102","author":"JC Roach","year":"2005","unstructured":"Roach JC, Glusman G, Rowen L et al (2005) The evolution of vertebrate Toll-like receptors. Proc Natl Acad Sci USA 102:9577\u20139582. https:\/\/doi.org\/10.1073\/pnas.0502272102","journal-title":"Proc Natl Acad Sci USA"},{"key":"4036_CR39","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1128\/CMR.05013-11","volume":"25","author":"F Robert-Gangneux","year":"2012","unstructured":"Robert-Gangneux F, Darde ML (2012) Epidemiology of and diagnostic strategies for toxoplasmosis. Clin Microbiol Rev 25:264\u2013296. https:\/\/doi.org\/10.1128\/CMR.05013-11","journal-title":"Clin Microbiol Rev"},{"key":"4036_CR40","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12082274","author":"D Saka","year":"2020","unstructured":"Saka D, Gokalp M, Piyade B et al (2020) Mechanisms of T-cell exhaustion in pancreatic cancer. Cancers (basel). https:\/\/doi.org\/10.3390\/cancers12082274","journal-title":"Cancers (basel)"},{"key":"4036_CR41","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1158\/2326-6066.CIR-14-0235","volume":"3","author":"KL Sanders","year":"2015","unstructured":"Sanders KL, Fox BA, Bzik DJ (2015) Attenuated Toxoplasma gondii stimulates immunity to pancreatic cancer by manipulation of myeloid cell populations. Cancer Immunol Res 3:891\u2013901. https:\/\/doi.org\/10.1158\/2326-6066.CIR-14-0235","journal-title":"Cancer Immunol Res"},{"key":"4036_CR42","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2015.1104447","volume":"5","author":"KL Sanders","year":"2016","unstructured":"Sanders KL, Fox BA, Bzik DJ (2016) Attenuated Toxoplasma gondii therapy of disseminated pancreatic cancer generates long-lasting immunity to pancreatic cancer. Oncoimmunology 5:e1104447. https:\/\/doi.org\/10.1080\/2162402X.2015.1104447","journal-title":"Oncoimmunology"},{"key":"4036_CR43","doi-asserted-by":"publisher","first-page":"5997","DOI":"10.4049\/jimmunol.168.12.5997","volume":"168","author":"CA Scanga","year":"2002","unstructured":"Scanga CA, Aliberti J, Jankovic D et al (2002) Cutting edge: MyD88 is required for resistance to Toxoplasma gondii infection and regulates parasite-induced IL-12 production by dendritic cells. J Immunol 168:5997\u20136001. https:\/\/doi.org\/10.4049\/jimmunol.168.12.5997","journal-title":"J Immunol"},{"key":"4036_CR44","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21590","volume":"70","author":"RL Siegel","year":"2020","unstructured":"Siegel RL, Miller KD, Jemal A (2020) Cancer statistics, 2020. CA Cancer J Clin 70:7\u201330. https:\/\/doi.org\/10.3322\/caac.21590","journal-title":"CA Cancer J Clin"},{"key":"4036_CR45","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/CJI.0000000000000062","volume":"38","author":"KC Soares","year":"2015","unstructured":"Soares KC, Rucki AA, Wu AA et al (2015) PD-1\/PD-L1 blockade together with vaccine therapy facilitates effector T-cell infiltration into pancreatic tumors. J Immunother 38:1\u201311. https:\/\/doi.org\/10.1097\/CJI.0000000000000062","journal-title":"J Immunother"},{"key":"4036_CR46","doi-asserted-by":"publisher","first-page":"1769","DOI":"10.1136\/gutjnl-2013-306271","volume":"63","author":"IM Stromnes","year":"2014","unstructured":"Stromnes IM, Brockenbrough JS, Izeradjene K et al (2014) Targeted depletion of an MDSC subset unmasks pancreatic ductal adenocarcinoma to adaptive immunity. Gut 63:1769\u20131781. https:\/\/doi.org\/10.1136\/gutjnl-2013-306271","journal-title":"Gut"},{"key":"4036_CR47","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1038\/s41419-021-04487-w","volume":"13","author":"Y Sun","year":"2022","unstructured":"Sun Y, Han X, Shang C et al (2022) The downregulation of type I IFN signaling in G-MDSCs under tumor conditions promotes their development towards an immunosuppressive phenotype. Cell Death Dis 13:36. https:\/\/doi.org\/10.1038\/s41419-021-04487-w","journal-title":"Cell Death Dis"},{"key":"4036_CR48","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1016\/j.immuni.2019.03.011","volume":"50","author":"ED Tait Wojno","year":"2019","unstructured":"Tait Wojno ED, Hunter CA, Stumhofer JS (2019) The immunobiology of the interleukin-12 family: room for discovery. Immunity 50:851\u2013870. https:\/\/doi.org\/10.1016\/j.immuni.2019.03.011","journal-title":"Immunity"},{"key":"4036_CR49","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/j.coi.2013.01.006","volume":"25","author":"RH Vonderheide","year":"2013","unstructured":"Vonderheide RH, Bayne LJ (2013) Inflammatory networks and immune surveillance of pancreatic carcinoma. Curr Opin Immunol 25:200\u2013205. https:\/\/doi.org\/10.1016\/j.coi.2013.01.006","journal-title":"Curr Opin Immunol"},{"key":"4036_CR50","doi-asserted-by":"publisher","first-page":"3048","DOI":"10.1038\/onc.2016.458","volume":"36","author":"X Wang","year":"2017","unstructured":"Wang X, Lang M, Zhao T et al (2017) Cancer-FOXP3 directly activated CCL5 to recruit FOXP3(+)Treg cells in pancreatic ductal adenocarcinoma. Oncogene 36:3048\u20133058. https:\/\/doi.org\/10.1038\/onc.2016.458","journal-title":"Oncogene"},{"key":"4036_CR51","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.canlet.2018.03.040","volume":"425","author":"JW Xu","year":"2018","unstructured":"Xu JW, Wang L, Cheng YG et al (2018) Immunotherapy for pancreatic cancer: a long and hopeful journey. Cancer Lett 425:143\u2013151. https:\/\/doi.org\/10.1016\/j.canlet.2018.03.040","journal-title":"Cancer Lett"},{"key":"4036_CR52","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1074\/mcp.M116.063602","volume":"16","author":"Z Yang","year":"2017","unstructured":"Yang Z, Hou Y, Hao T et al (2017) A human proteome array approach to identifying key host proteins targeted by toxoplasma kinase ROP18. Mol Cell Proteom 16:469\u2013484. https:\/\/doi.org\/10.1074\/mcp.M116.063602","journal-title":"Mol Cell Proteom"},{"key":"4036_CR54","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1038\/nri3598","volume":"14","author":"F Yarovinsky","year":"2014","unstructured":"Yarovinsky F (2014) Innate immunity to Toxoplasma gondii infection. Nat Rev Immunol 14:109\u2013121. https:\/\/doi.org\/10.1038\/nri3598","journal-title":"Nat Rev Immunol"},{"key":"4036_CR55","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1136\/gutjnl-2016-312078","volume":"66","author":"Y Zhang","year":"2017","unstructured":"Zhang Y, Velez-Delgado A, Mathew E et al (2017) Myeloid cells are required for PD-1\/PD-L1 checkpoint activation and the establishment of an immunosuppressive environment in pancreatic cancer. Gut 66:124\u2013136. https:\/\/doi.org\/10.1136\/gutjnl-2016-312078","journal-title":"Gut"},{"key":"4036_CR56","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-002970","author":"YC Zhu","year":"2021","unstructured":"Zhu YC, Elsheikha HM, Wang JH et al (2021) Synergy between Toxoplasma gondii type I DeltaGRA17 immunotherapy and PD-L1 checkpoint inhibition triggers the regression of targeted and distal tumors. J Immunother Cancer. https:\/\/doi.org\/10.1136\/jitc-2021-002970","journal-title":"J Immunother Cancer"}],"container-title":["Journal of Cancer Research and Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-022-04036-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00432-022-04036-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-022-04036-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,13]],"date-time":"2022-09-13T08:16:25Z","timestamp":1663056985000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00432-022-04036-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,12]]},"references-count":56,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["4036"],"URL":"https:\/\/doi.org\/10.1007\/s00432-022-04036-8","relation":{},"ISSN":["0171-5216","1432-1335"],"issn-type":[{"value":"0171-5216","type":"print"},{"value":"1432-1335","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,12]]},"assertion":[{"value":"2 March 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 April 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 May 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The author(s) declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All animal protocols were approved by the Institutional Animal Care and Use Committee at Sun Yat-sen University for animal welfare.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}